The role of photodynamic therapy in retinal vascular disease

Retinal Vascular Disease

Volumn , Issue , 2007, Pages 239-255

  Jurklies, Bernhard ^a   Bornfeld, Norbert ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891967859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-29542-6_14     Document Type: Chapter

References (90)

1. Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R (2006) Three cases of large retinal capillary hemangioma treated with verteporfin and photodynamic therapy. Arch Ophthalmol 123:328-332
2. Allison BA, Waterfield E, Richter AM, Levy JG (1991) The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 54:709-715
3. Anastassiou G, Bornfeld N, Schüler AO, Schilling H, Weber S, Flühs D, Jurklies B, Sauerwein W (2006) Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina. Br J Ophthalmol 90:447-450
4. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Pho-todynamic Therapy Study Group (2004) Acute severe visual acuity decrease after photodynamic therapy with vertepor-fin: case reports from randomized clinical trials-TAP and VIP report No. 3. Am J Ophthalmol 137:683-696
5. Atebara NH (2002) Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 134:788-790
6. Bakri SJ, Sears JE, Singh AD (2005) Transient closure of a retinal capillary hemangioma with verteporfin. Retina 25:1103-1104
7. Barbazetto IA, Smith RT (2003) Vasoproliferative tumor of the retina treated with PDT. Retina 23:565-567
8. Berger JW (1999) Macular laser tissue interactions: implications for treatment and prophylaxis, Chapter 14. In: Berger JW, Fine SL, Maguire MG (eds) Age-related macular degeneration. Mosby, St. Louis, pp 249-261
9. Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E (2006) Photodynamic therapy for vasoproliferative retinal tumors. Retina 26:404-409
10. Bloom SM, Brucker AJ (1997) Principles of photocoagulation. In: Laser surgery of the posterior eye segment, Chapter 1. Lippincott-Raven, Philadelphia, pp 3-36
11. De Lahitte GD, Cohen SY, Gaudric A (2004) Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal teleangiectasis without subretinal neovascularization. Am J Ophthalmol 138:892-894
12. De Vree WJ, Essers MC, Koster JF, Sluiter W (1997) Role of interleukin 1 and granulocyte colony stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyo-sarcoma tumors. Cancer Res 57:2555-2558
13. Dougherty TJ (1984) Photodynamic therapy of malignant tumors. Crit Rev Oncol Hematol 2:83-116
14. Dougherty TJ, Gomer CJ, Henderson B, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889-905
15. Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with Verteporfin in subfoveal choroidal neovascularization to central serous chorioretinopathy. Arch Ophthalmol 122: 37-41
16. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI (1990) Effect of photodynamic therapy on tumor necrosis production by murine macrophages. J Natl Cancer Inst 82:34-39
17. Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323-328
18. Gass JD, Blodi B (1993) Idiopathic juxtafoveolar retinal tele-angiectasis. Update of classification and follow-up study. Ophthalmology 100:1536-1546
19. Ghazi NA, Jabbour NM, De La Cruz ZC, Green WR (2001) Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21:478-486
20. 2+ ATPase in R3230AC rat mammary ade-nocarcinomas. Cancer Res 48:3360-3366
21. Gomer CJ (1989) Photodynamic therapy in the treatment of malignancies. Semin Hematol 26:24-34
22. Haimovici R, Kramer M, Miller JW, et al. (1997) Localization of the lipoprotein delivered benzoporphyrin derivative in the rabbit. Curr Eye Res 16:83-90
23. Heimann H, Bornfeld N, Vij O, Coupland SE, Bechrakis NE, Kellner U, Foerster MH (2000) Vasoproliferative tumors of the retina. Br J Ophthalmol 84:1162-1169
24. Henderson BW, Dougherty TJ (1992) How does photody-namic therapy work? Photochem Photobiol 55:145-157
25. Husain D, Miller JW, Michaud N, Connolly E, Flotte T, Gra-goudas E (1996) Intravenous infusion of liposomal benzo-porphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978-986
26. Husain D, Kramer M, Kenny AG, Michaud N, Flotte T, Gra-goudas E, Miller JW (1999) Effects of photodynamic therapy on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322-2331
27. Hussain N, Das T, Sumasri K, Ram LS (2005) Bilateral sequential photodynamic therapy for subretinal neovascu-larization with type 2A parafoveal teleangiectasis. Am J Ophthalmol 140:333-335
28. Johnson MW, Flynn HW, Gass JDM (1992) Pars plana vit-rectomy and direct diathermy for complications of multiple retinal angiomas. Ophthalmic Surg 23:47-50
29. Jori G (1990) Factors controlling the selectivity and efficiency of tumor damage in photodynamic therapy. Lasers Med Sci 5:115-120
30. Jurklies B, Anastassiou G, Ortmans S, Schüler A, Schilling H, Schmidt-Erfurth U, Bornfeld N (2003) Photodynamic therapy using Verteporfin in circumscribed choroidal hem-angioma. Br J Ophthalmol 87:84-89
31. Jurklies B, Bornfeld N, Schilling H (2006) Photodynamic therapy using Verteporfin for choroidal neovascularization associated with angioid streaks-long-term effects. Ophthalmic Res 38:209-217
32. Korbelik M (1996) Induction of tumor immunity by photo-dynamic therapy. J Clin Laser Med Surg 14:329-334
33. Korbelik M, Krosl G (1994) Enhanced macrophage cytotox-icity against tumor cells treated with photodynamic therapy. Photochem Photobiol 60:497-502
34. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte T, Gragoudas E (1996) Liposomal benzoporphyrin derivative Verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427-438
35. Kreusel KM, Bornfeld N, Lommatzsch A, et al. (1998) Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 105:1386-1392
36. McDonald HR (2003) Diagnostic and therapeutic challenges. Juxtapapillary retinal capillary hemangioma. Retina 23:86-91
37. Menchini U, Visgili G, Introini U, Bandello F, Ambesi-Impi-ombato M, Pece A, Parodi MB, Giacomelli G, Capobianco B, Varano M, Brancato R (2004) Outcome of choroidal neovas-cularization in angioid streaks after photodynamic therapy. Retina 24:763-771
38. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, Flotte T, Haimovici R, Gragoudas E (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113:810-818
39. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras C, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane A-M, Birngruber R, van den Berg H, Strong A, Manjuris U, Todd G, Fsadni M, Bressler NM, Gragoudas E (1999) Photo-dynamic therapy with verteporfin for choroidal neovascu-larization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161-1173
40. Moan J, Christensen T (1981) Cellular uptake and photody-namic effects of hematoporphyrin. Photochem Photobiol 2:291-299
41. Moan J, McGhie J, Jacobsen PB (1983) Photodynamic effects of cells in vitro exposed to hematoporphyrin derivative in light. Photochem Photobiol 37:599-604
42. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C (1987) Photosensitizing efficiencies, tumor and cellular uptake of different photosensitizing drugs relevant for pho-todynamic therapy of cancer. Photochem Photobiol 46: 713-721
43. Moore AT, Maher ER, Rosen P, et al. (1991) Ophthalmologi-cal screening for von Hippel Lindau disease. Eye 5:723-728
44. Obochi MO, Ratkay LG, Levy JG (1997) Prolonged skin allo-graft survival after photodynamic therapy associated with modification of donor skin antigenicity. Transplantation 63:810-817
45. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Ver-ougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photo-dynamic therapy for classic choroidal neovascularization in young females (2004). Am J Ophthalmol 138:803-808
46. Potter MJ, Szabo SM, Sarraf D, Michels R, Schmidt-Erfurth U (2006) Photodynamic therapy for subretinal neovascula-rization in type 2A idiopathic juxtafoveolar teleangiectasis. Can J Ophthalmol 41:34-37
47. Reinke MH, Canakis C, Husain D, et al. (1999) Verteporfin photodynamic therapy retreatment of normal retina and choroids in the cynomolgus monkey. Ophthalmology 106: 1915-1923
48. Richter AM, Kelly B, Chow J, et al. (1987) Preliminary studies on a more effective phototoxic agent than hematopor-phyrin. J Natl Cancer Inst 79:1327-1332
49. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D, Levy JG (1990) Biodistribution of tritiated benzoporphyrine derivative (3H-BPD-MA) a new potent photosensitizer in normal and tumor bearing mice. J Photochem Photobiol 53:231-244
50. Richter AM, Waterfield E, Jain AK, Allison B, Sternberg ED, Dolphin D, Levy JG (1991) Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br J Cancer 63:87-93
51. Rodriguez-Coleman H, Spaide R, Yanuzzi L (2002) Treatment of angiomatous lesions of the retina with photody-namic therapy. Retina 22:228-232
52. Rosenfeld PJ, Saperstein DA, Bressler NM, Reaves TA, Sick-enberg M, Rosa RH, Sternberg P, Aaberg TM Sr, Aaberg TM Jr, for the Verteporfin in Ocular Histoplasmosis Study Group (2004) Photodynamic therapy with Verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study. Ophthalmology 111:1725-1733
53. Rubin GS, Bressler N, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No.4. Retina 22:536-544
54. Ryan SJ (1982) Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol 100:1804-1809
55. Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH, Sick-enberg M, Sternberg P, Aaberg TM Sr, Aaberg TM Jr, Reaves TA, for the Verteporfin in Ocular Histoplasmosis (VOH) Study group (2002) Ophthalmology 109:1499-1505
56. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Oph-thalmol 240:748-757
57. Schmidt-Erfurth U, Bauman W, Gragoudas E (1994a) Pho-todynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101:89-99
58. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R (1994b) Vascular targeting in pho-todynamic occlusion of subretinal vessels. Ophthalmology 101:1953-1961
59. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T (1997) Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Ophthalmol 75:54-61
60. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. (1999) Photodynamic therapy with verteporfin for choroidal neo-vascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117:1177-1187
61. Schmidt-Erfurth U, Michels S, Kusserow C, Jurklies B, Augustin A (2002a) Photodynamic therapy for symptomatic choroidal hemangioma: Visual and anatomic results. Ophthalmology 109:2284-2294
62. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehardt U, Vie-stenz A, Naumann GOH (2002b) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835-844
63. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002c) Photodynamic effects on choroidal neovasculari-zation and physiological choroids. Invest Ophthalmol Vis Sci 43:830-841
64. Schmidt-Erfurth U, Kusserow C, Barabazetto IA, Laqua H (2002d) Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 109:1256-1266
65. Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal teleangiectasis. Indian J Ophthalmol 53:61-63
66. Shields JA (1993) Response of retinal capillary hemangio-ma to cryotherapy. Arch Ophthalmol 111:551
67. Shields JA, Shields CL (1999) Vascular tumors of the retina and optic disc. In: Shields JA, Shields CL (eds) Atlas of intraocular tumors, Chapter 17. Lippincott Williams and Wilkins, Philadelphia, pp 243-267
68. Sickenberg M, Schmidt-Erfurth U, Miller JW Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gra-goudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM (2000) A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 118:327-336
69. Singh AD, Nouri M, Shields CL, Shields JA, Perez N (2002) Treatment of retinal capillary hemangioma. Ophthalmology 109:1799-1806
70. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal tele-angiectasis. Am J Ophthalmol 137:812-819
71. Spaide RF, Freund KB, Slakter J, Sorenson J, Yanuzzi LA, Fisher Y (2002a) Treatment of subfoveal choroidal neovas-cularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545-549
72. Spaide RE, Donsoff I, Lam DL, Yanuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002b) Treatment of poly-poidal choroidal vasculopathy with photodynamic therapy. Retina 22:529-535
73. Steinert RF, Puliafito CA (1985) The neodymium:YAG laser in ophthalmology: principles and clinical practice of pho-todisruption. Saunders, Philadelphia
74. Szabo A, Gehl Z, Seres A (2005) Photodynamic (vertepor-fin) therapy for retinal capillary hemangioma, with monitoring of feeder and draining blood vessel diameters. Acta Ophthalmol Scan 83:512-513
75. Thomas JP, Girotti AW (1989) Role of lipid peroxidation in hematoporphyrin derivative-sensitized photokilling of tumor cells: protective effects of glutathione peroxidase. Cancer Res 49:1682-1686
76. Treatment of Age-Related Macular Degeneration with Pho-todynamic Therapy (TAP) Study Group (1999) Photody-namic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117:1329-1345
77. Treatment of Age-Related Macular Degeneration with Pho-todynamic Therapy (TAP) Study Group (2001) Photody-namic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119:198-207
78. Treatment of Age-Related Macular Degeneration with Pho-todynamic Therapy (TAP) Study Group (2002a) Photody-namic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report 3. Arch Ophthal-mol 120:1443-1454
79. Treatment of Age-Related Macular Degeneration with Pho-todynamic Therapy (TAP) Study Group (2002b) Photody-namic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: three-year results of an open-label extension of 2 randomized clinical trials-TAP report 5. Arch Ophthalmol 120: 1307-1314
80. Treatment of Age-Related Macular Degeneration with Pho-todynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Groups (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report 1 (2003). Am J Ophthalmol 136:407-418
81. Valmaggia C, Niederberger H, Helbig H (2002) Photody-namic therapy for choroidal neovascularization in fundus flavimaculatus. Retina 22:111-113
82. Verbraak FD, Schlingemann RO, Keunen JE, de Smet MD (2003) Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy. Graefes Arch Clin Exp Ophthalmol 241:891-898
83. Verteporfin in Photodynamic Therapy Study Group (2001a) Photodynamic therapy of subfoveal choroidal neo-vascularization in pathologic myopia with Verteporfin. 1-year results of a randomized clinical trial-VIP report No. 1. Ophthalmology 108:841-852
84. Verteporfin in Photodynamic Therapy Study Group (2001b) Verteporfin therapy of subfoveal choroidal neovas-cularization in age-related macular degeneration: Two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verte-porfin in photodynamic therapy report 2. Am J Ophthalmol 131:541-560
85. Verteporfin in Photodynamic Therapy Study Group (2003) Verteporfin of subfoveal choroidal neovascularization in pathologic myopia. 2 year results of a randomized clinical trial-VIP report No. 3. Ophthalmology 110:667-673
86. Verteporfin Roundtable Participants (2005) Guidelines for using Verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina 25:119-134
87. Visudyne in Minimally Classic Choroidal Neovascularizati-on Study Group (2005) Verteporfin therapy of subfoveally minimally classic choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 123:448-457
88. Volden G, Christensen T, Moan J (1981) Photodynamic membrane damage of hematoporphyrin derivative treated NHIK 3025 cells in vitro. Photobiochem Photobiophy 3: 105-111
89. Wachtlin J, Heimann H, Behme T, Foerster MH (2003a) Long-term results after photodynamic therapy with cho-roidal neovascularization secondary to inflammatory cho-rioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241:899-906
90. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH (2003b) Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 241:518-521